Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Biomarkers

Quantum Molecular Pharmaceuticals, Inc.

Parents

246 Matheson Blvd East
Canada L4Z 1X1
Developmental stage company looking to impact the radiopharmaceutical market
dwilson@quantumpharma.com
Especially of FDG, the primary radiopharmaceutical used in the performance of PET (“Positron Emission Tomography”) scans.
FDG- Fluorodeoxyglucose F18, (2-deoxy-2[18F]fluoro-D-glucose),
J. David Wilson, CEO
Mississauga, Ontario
Production/distribution of Positron Emitting Radiopharmaceuticals (PERs);
Radiopharmaceuticals are designed to accumulate in the body region or organ of interest and have measurable decay and radiation
Three Objectives: